Table 5. Multivariable analysis of OS... | American Society of Hematology

Table 5.

Multivariable analysis of OS and LFS for subgroups

Subgroup	HR	95% CI	P
OS
CD28 vs 4-1BB	0.609	0.254-1.461	.267
With vs without EMD	0.455	0.196-1.056	.067
No previous transplant vs posttransplant relapse	2.184	0.830-5.744	.113
BM blasts ≤20% vs >20%	2.968	1.270-6.901	.012*
TP53⁺ mutation vs TP53^– mutation	0.189	0.073-0.488	.001†
CAR T-cell bridged into allo-HSCT vs CAR T-cell therapy alone	12.250	4.774-31.438	<.001†
LFS
CD28 vs 4-1BB	0.927	0.351-2.452	.879
Without vs with EMD	1.192	0.455-3.123	.720
No previous transplant vs posttransplant relapse	2.881	0.939-8.837	.064
BM blasts ≤20% vs >20%	1.569	0.610-4.039	.350
TP53⁺ mutation vs TP53^– mutation	0.279	0.092-0.849	.025*
CAR T-cell bridged into allo-HSCT vs CAR T-cell therapy alone	26.430	7.292-95.793	<.001†

Subgroup	HR	95% CI	P
OS
CD28 vs 4-1BB	0.609	0.254-1.461	.267
With vs without EMD	0.455	0.196-1.056	.067
No previous transplant vs posttransplant relapse	2.184	0.830-5.744	.113
BM blasts ≤20% vs >20%	2.968	1.270-6.901	.012*
TP53⁺ mutation vs TP53^– mutation	0.189	0.073-0.488	.001†
CAR T-cell bridged into allo-HSCT vs CAR T-cell therapy alone	12.250	4.774-31.438	<.001†
LFS
CD28 vs 4-1BB	0.927	0.351-2.452	.879
Without vs with EMD	1.192	0.455-3.123	.720
No previous transplant vs posttransplant relapse	2.881	0.939-8.837	.064
BM blasts ≤20% vs >20%	1.569	0.610-4.039	.350
TP53⁺ mutation vs TP53^– mutation	0.279	0.092-0.849	.025*
CAR T-cell bridged into allo-HSCT vs CAR T-cell therapy alone	26.430	7.292-95.793	<.001†

P < .05.

P < .01.